Mpm Oncology Innovations Fund Lp - Net Worth and Insider Trading

Mpm Oncology Innovations Fund Lp Net Worth

The estimated net worth of Mpm Oncology Innovations Fund Lp is at least $42 Million dollars as of 2024-11-05. Mpm Oncology Innovations Fund Lp is the 10% Owner of Werewolf Therapeutics Inc and owns about 18,038,516 shares of Werewolf Therapeutics Inc (HOWL) stock worth over $42 Million. Details can be seen in Mpm Oncology Innovations Fund Lp's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Mpm Oncology Innovations Fund Lp has not made any transactions after 2021-05-04 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Mpm Oncology Innovations Fund Lp

Mpm Oncology Innovations Fund Lp Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Mpm Oncology Innovations Fund Lp owns 1 companies in total, including Werewolf Therapeutics Inc (HOWL) .

Click here to see the complete history of Mpm Oncology Innovations Fund Lp’s form 4 insider trades.

Insider Ownership Summary of Mpm Oncology Innovations Fund Lp

Ticker	Comapny	Transaction Date	Type of Owner
HOWL	Werewolf Therapeutics Inc	2021-05-04	10 percent owner

Mpm Oncology Innovations Fund Lp Latest Holdings Summary

Mpm Oncology Innovations Fund Lp currently owns a total of 1 stock. Mpm Oncology Innovations Fund Lp owns 18,038,516 shares of Werewolf Therapeutics Inc (HOWL) as of May 4, 2021, with a value of $42 Million.

Latest Holdings of Mpm Oncology Innovations Fund Lp

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
HOWL	Werewolf Therapeutics Inc	2021-05-04	18,038,516	2.31	41,668,972

Holding Weightings of Mpm Oncology Innovations Fund Lp

Mpm Oncology Innovations Fund Lp Form 4 Trading Tracker

According to the SEC Form 4 filings, Mpm Oncology Innovations Fund Lp has made a total of 1 transactions in Werewolf Therapeutics Inc (HOWL) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Werewolf Therapeutics Inc is the acquisition of 245,000 shares on May 4, 2021, which cost Mpm Oncology Innovations Fund Lp around $4 Million.

Insider Trading History of Mpm Oncology Innovations Fund Lp

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Mpm Oncology Innovations Fund Lp Trading Performance

GuruFocus tracks the stock performance after each of Mpm Oncology Innovations Fund Lp's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mpm Oncology Innovations Fund Lp is 0.94%. GuruFocus also compares Mpm Oncology Innovations Fund Lp's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mpm Oncology Innovations Fund Lp within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Mpm Oncology Innovations Fund Lp's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Mpm Oncology Innovations Fund Lp

Average Return

Average return per transaction

Outperforming Transactions

0 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-22.89
Relative Return to S&P 500(%)	-24.46

Mpm Oncology Innovations Fund Lp Ownership Network

Ownership Network List of Mpm Oncology Innovations Fund Lp

No Data

Ownership Network Relation of Mpm Oncology Innovations Fund Lp

Mpm Oncology Innovations Fund Lp Owned Company Details

What does Werewolf Therapeutics Inc do?

Who are the key executives at Werewolf Therapeutics Inc?

Mpm Oncology Innovations Fund Lp is the 10 percent owner of Werewolf Therapeutics Inc. Other key executives at Werewolf Therapeutics Inc include director & 10 percent owner Ra Capital Healthcare Fund Lp , Chief Technology Officer Chulani Karunatilake , and Chief Operating Officer Reid Leonard .

Werewolf Therapeutics Inc (HOWL) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Werewolf Therapeutics Inc (HOWL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Werewolf Therapeutics Inc (HOWL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Werewolf Therapeutics Inc (HOWL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Werewolf Therapeutics Inc Insider Transactions

No Available Data

Mpm Oncology Innovations Fund Lp Mailing Address

Above is the net worth, insider trading, and ownership report for Mpm Oncology Innovations Fund Lp. You might contact Mpm Oncology Innovations Fund Lp via mailing address: 450 Kendall Street, Cambridge Ma 02142.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.